545 related articles for article (PubMed ID: 31084317)
1. Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease.
Lluri G; Lin J; Reardon L; Miner P; Whalen K; Aboulhosn J
World J Pediatr Congenit Heart Surg; 2019 May; 10(3):292-295. PubMed ID: 31084317
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
3. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
4. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.
Martens P; Lambeets S; Lau CW; Dupont M; Mullens W
Acta Cardiol; 2019 Apr; 74(2):115-122. PubMed ID: 29909743
[TBL] [Abstract][Full Text] [Related]
5. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
6. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
7. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
12. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.
Antol DD; Casebeer AW; DeClue RW; Stemkowski S; Russo PA
Adv Ther; 2018 Jun; 35(6):785-795. PubMed ID: 29777521
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
16. Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
Dashwood A; Vale C; Laher S; Chui F; Rheault H; Gan J; Wong YW
Heart Lung Circ; 2020 Nov; 29(11):1688-1695. PubMed ID: 32327307
[TBL] [Abstract][Full Text] [Related]
17. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
18. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Cosentino ER; Degli Esposti D; Miceli R; Bentivenga C; Landolfo M; Fg Cicero A; Berardi E; Spinardi L; Magri G; Dugato V; Borghi C
Curr Med Res Opin; 2019 Mar; 35(sup1):9-12. PubMed ID: 30864900
[TBL] [Abstract][Full Text] [Related]
20. Health-Related Quality of Life Outcomes in PARADIGM-HF.
Lewis EF; Claggett BL; McMurray JJV; Packer M; Lefkowitz MP; Rouleau JL; Liu J; Shi VC; Zile MR; Desai AS; Solomon SD; Swedberg K
Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28784687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]